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Coming from Crimea, the Black Death spread to Western Europe and North Africa during the 
1340s. From 1346 to 1352, the plague killed an estimated 25-40% of Europeans of all age-
groups [1] , i.e. 30 to 60% of Europe population. One of the earliest and most widely accepted 
explanations was that God was punishing humanity for their sins. One remedy for the curse 
was to do penitence. Thus in 1348 there rapidly arose a mass movement of flagellation [2]. In 
fact flagellation could not really help against such threat. The Black Death or Bubonic plague 
is caused by Yersinia pestis, a Eubacteria discovered in 1894 by Alexandre Yersin. It is 
transmitted by the bite of the flea Xenopsylla cheopsis. This flea lives by feeding the blood of 
many species besides man but its most preferred relationship is with the black rat (Rattus 
rattus). Fossilized remains of the plague flea have been found in large numbers in Amarna, 
Egypt [3, 4] about 1350 BC, and thus could be directly linked to the events described in the 
Book of Samuel [5, 6]. During the epidemic of Bubonic plague in London in 1665-1666, the 
known treatments were made use of, e.g. the so-famous Theriac or Venice Treacle which is 
used from the time of ancient Rome as a remedy against poison [7]. Since then, more 
specialized and novel treatments have been developed. However, since the characterization of 
Yersinia pestis, numerous drugs have been developed against it, e.g. gentamicin or 
doxycycline [8].. These researches had been carried out using more elaborated biochemical, 
biophysical and biological approaches.  
However, with the explosion of genomic sequencing -815 complete genomes are made 
available for the scientific community (as of January 2009) [9]- complementing the 
experimental information with the increasing power of computational facilities has given new 
opportunities to fight against infectious diseases and to identify pertinent drug targets with 
novel methodologies. The in silico approaches have been playing a prominent role in this 
research area during the last decade. This special issue presents the various views about the 
different in silico approaches by some of the best international research teams. Pr. 
Sowdhamini’s group has compared different genomes from a group of enterobacteric 
pathogens known to share similar genomic content but having diverse host specificities and 
distinct disease symptoms [10]. The detailed cross-genome analysis of these subspecies 
provides an understanding of the diversity and unique attributes defined in the individual 
Salmonella enterica genomes. Pr. Srinivasan’s group develops new approaches dedicated to 
Plasmodium falciparum analysis, the most important causative agent of malaria [11]. The 
latter has a very specific genome and thus needs to be studied thoroughly and specifically. 
They present examples of protein-protein interactions across human and P. falciparum, 
potentially happening during pathogenesis. Pr. Deléage’s work deals with Hepatitis C Virus 
(HCV). They have developed the European Hepatitis C Virus Database (euHCVdb, 
http://euhcvdb.ibcp.fr/), a collection of relevant structural models that can help in drug design , 
with strategies for combating resistance to drug treatment and to have a better understanding 
structural biology of the HCV [12].  They present some examples of the use of the database.  
Within this new research field, an important axis of research concerns the transmembrane 
proteins, they represent about ~25% of proteins coded by genomes. Moreover, they serve as 
targets for about 2/3
rd
 of the marketed drugs out of which 50% specifically target a GPCR 
[13]. As these proteins are embedded in a lipid membrane that constitutes a very specific 
environment, they represent only about ~1% of all the available structures, owing to the 
difficulties associated with their crystallization [14]. . Thus alternative approaches are 
required to obtain structural information. Consequently methods aiming at constructing 3D 
structural models are becoming an important area of research, for understanding biological 
mechanisms and interactions [15]. Wang and Duan summarizes the recent computational 
researches done on CC-chemokine receptor 5 (CCR5), an essential co-receptor for HIV entry 
into the cells and show how the recently solved GPCR structures would provide new insights 
into the modeling of CCR5-inhibitor binding [16].  Pr. Etchebest’s group work focus on an 
unorthodox chemokine receptor, named DARC, which binds chemokines of both CC and 
CXC classes and do not couple to G proteins and activate their signaling pathways. DARC 
had also been associated to cancer progression, numerous inflammatory diseases, and possibly 
to AIDS. We show our recent development of the construction and analyzes of structural 
models of DARC [17]. We underline the difficulty to propose pertinent structural models of 
transmembrane protein using comparative modeling process, and also highlight the use of 
other dedicated approaches like the analysis using Protein Blocks [18-20].  Finally, we 
present the recent development of protein – protein docking carried out between DARC 
structural models and CXCL-8 structures using an innovative hierarchal search procedure, 
based on both rigid and flexible docking [21]. 
Dealing with Plasmodium falciparum, Pr. Louw and co-workers describes the peculiarities of 
malaria proteins and various in silico strategies to select and allow descriptions of the 
molecular structures of potential drug target candidates. They also present the subsequent 
rational approaches that can be used for drug design. The uniqueness of this organism makes 
the in silico approaches for the specific design of an inhibitor drugs invaluable and as an 
economic and rational alternative to chemical library screening [22]. Following the same 
approach, Murphy and Brown focus on another major global healthcare problem: the 
resurgence of drug resistant Mycobacterium tuberculosis. The identification of genes essential 
for the bacterium in its dormancy phase infections, is a key strategy in the development of 
new anti-Mycobacterium tuberculosis therapeutics. They present the applications of advanced 
computational analyses to predict potential drug targets and also highlight the difficulties 
associated with translating in silico predictions to effective clinical therapies [23]. Dr. 
Watowich’s group works on the Dengue virus, one of the most important global pathogens 
which represent a global pandemic. The resurgence of Dengue virus since the 70’s has 
occurred after the cessation of mosquito control measures. The authors summarize the biology 
of this Flaviviridae and especially its different proteins. They highlight the possibility of 
utilizing Dengue virus nonstructural proteins as potential drug targets and also give an 
extensive overview of computational methods for drug discovery like docking, HTS or ligand 
compound database [24]. 
To conclude this special issue, we present three papers that deal with impressive novel 
methodological developments. The first one is by Dr. Doppelt-Azeroual and co-workers. As 
protein structures are directly associated with their functions that often involves the binding of 
other proteins, ligands, nucleic acids or other compounds, the knowledge of 3D structures can 
explain biological mechanisms and help to design drugs. They have developed MED-SuMo 
[25], an efficient method that can compare and detect binding sites. This tool can locate 
similar regions on macromolecular surfaces, associated to a defined chemical function. In this 
review, they present the recent improvements in MED-SuMo and its interest in several 
applications in biology, e.g., structural superimposition, pocket profiling, drug repurposing 
and an automated function binding sites classification. A new protocol combines a fragment-
based approach and local similarities of protein surfaces [26]. Another one deals with the use 
of powerful Grid computing in the life science domain. Grid computing is an exciting new 
technology promising to revolutionize many services already offered by the internet. Grids are 
defined as a fully distributed, dynamically reconfigurable, scalable and autonomous 
infrastructure to provide location independent, pervasive, reliable, secure and efficient access 
to a coordinated set of services encapsulating and virtualizing resource [27]. Dr. Breton and 
collaborators have explored some innovative in silico approaches to better tackle avian flu, 
taking advantage of the very large computing resources available on international grid 
infrastructures. Grids are used to study the impact of mutations on the effectiveness of 
existing drugs against H5N1 and to find potential new leads active on mutated strains [28]. 
The third one concludes this issue by presenting the difficult problem of text mining. As 
nowadays, the number of publications has increased tremendously, it has a crucial issue. The 
solution proposed by Vellay and collaborators are implemented inside Pipeline Pilot [29]. 
This is a famous application designed to manipulate and analyze huge quantities of data in 
real time. This approach, known as “data pipelining”, uses a data flow framework to describe 
the processing of data [30]. After presenting the core of the Bibliography Platform protocol, 
the authors gives a pertinent example of the relevance of their approach. In the context of the 
neglected disease Leishmaniasis, this interface presents an overview allowing a fast 
understanding of the topic, an appreciation of its growing trend, and an instant identification 
of the most prolific authors and most popular journals in the disease area [31]. 
The quality of articles in this special issue depends on the authors who have clearly done a 
terrific job, and also on those individuals who lend their expertise to review manuscripts. On 
behalf of myself and the authors of papers published in this issue, I express my sincere thanks 
and appreciation to the individuals who generously gave their time to review one or more 
manuscripts. I would also like to thanks people of my team, especially Catherine Etchebest, 
Agnel Praveen Joseph and Aurélie Bornot for their help. 
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